© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
July 23rd 2021
David R. Gandara, MD, discusses recent developments in HER2-targeted therapies as a treatment for patients with non-small cell lung cancer.
Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.
August 17th 2021
Edgardo S. Santos, MD, discusses the potential role for CEACAM5- and KEAP1-targeted therapies in non–small cell lung cancer.
Erin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.
Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the rationale to target TROP-2 in lung cancer.